



2015-04-23

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SWITZERLAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

SciBase announces its intention to launch an Initial Public Offering and listing on Nasdaq First North

SciBase today announces its intention to proceed with an Initial Public Offering on Nasdaq First North. It is expected that the first day of trading will occur in June 2015. Further announcements relating to the Initial Public Offering will be made in due course.

SciBase is a Swedish medical technology company that has developed Nevisense, a unique point of care device for the accurate detection of malignant melanoma, the most deadly type of skin cancer. Nevisense has attracted widespread interest amongst dermatologists as the first non-visual point-of-care melanoma detection system, using Electrical Impedance Spectroscopy (EIS) to objectively analyze lesions of concern. The ability of Nevisense to accurately detect melanoma has been proven in the world's largest prospective study of its kind, published last year in the British Journal of Dermatology. The product has been launched in Australia, Germany, UK, Belgium and the Nordic markets and SciBase expects to launch further markets this year.

In order to further support SciBase's strategy and the future development of its business, the Company's current principal shareholders (SEB Venture Capital, SEB Pensionsstiftelse, Fouriertransform, and Omega Fund IV, L.P.) deem that a listing of the Company's shares is the logical next step for SciBase, enabling access to capital through the Swedish and international capital markets. Furthermore, a stock exchange listing is expected to contribute to increased recognition and brand awareness of SciBase as a medical technology company among current and potential customers. For these reasons, the Company's Board of Directors will apply for listing on Nasdaq First North.

Pareto Securities has been appointed Sole Manager and Bookrunner in connection with the contemplated IPO.

Offering highlights

The initial public offering of SciBase will comprise newly issued shares for the main purposes of financing the "Premarket Approval" process with the FDA and subsequent market introduction in the US, expanding sales and marketing in Europe and Australia, and developing the next generation of the Nevisense device.

The principal shareholders intend to participate in the offering with an aggregate amount of SEK 50 million. No secondary shares will be offered.

Simon Grant, CEO of SciBase comments:

"Last year, our compelling pivotal clinical trial results were published and since then we have seen a steadily increasing interest in Nevisense, both from physicians and distributors. This shows that our science based approach in developing Nevisense has paid off. Our focus today is the

continued commercialization and expansion of the company and the planned IPO would help us in achieving these goals”, says Simon Grant.

About Skin Cancer

Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.

About SciBase and Nevisense

SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at Karolinska Institute in Stockholm and at SciBase. The device is designed to provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result.

A video describing the Nevisense method is available on: www.scibase.se/en/the-nevisense-product and further information is also available on www.scibase.com.

For more information, please contact:

Simon Grant, CEO

Tel: +46 72 887 43 99

Email: simon.grant@scibase.com

IMPORTANT NOTICE

This announcement is not and does not form a part of any offer for sale of securities.

Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, New Zealand, Hong Kong, Japan, Singapore, Switzerland, South Africa or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.

Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.

In any EEA Member State other than Sweden that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.